CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 340 enrolled
Drug / intervention
Ivermectin Tabletsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04422561
NCT04422561Phase 3Completed
CompareCT.gov

Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contact for Patient With COVID-19

Zagazig University·interventional·Posted Jun 9, 2020·Updated Aug 27, 2020

In Brief

A Phase 3 clinical trial evaluating Ivermectin Tablets for COVID. Completed, enrolled 340 participants across 1 site.

Detailed Summary

asymptomatic family close contact of confirmed COVID -19 patient will receive prophylactic ivermectin and will be followed up for 14 days for any symptoms \& diagnosis of COVID -19

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID
CountriesEgypt
Collaborators--

Timeline

Phase 3CompletedFinished
202120222023202420252026
First PostedJun 9, 2020
Enrollment StartMay 31, 2020
Primary CompletionJul 14, 2020
Study CompletionJul 27, 2020
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.1 years ago

Interventions

Ivermectin Tabletsdrug

two doses 72 hours apart